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Abstract
Background: Ethnic differences have been reported with regard to several medical therapies. The aim of this study
was to investigate the relation between ethnicity and thrombolysis in stroke patients.
Methods: Retrospective single-centre study. Patients admitted with an ischemic stroke between 2003 and 2008
were included. Ethnicity was determined by self-identification and stratified into white and non-white (all other
ethnicities). The main outcome measure was the difference in thrombolysis rate between white and non-white
patients. Logistic regression analysis was used to identify potential confounders of the relation between ethnicity
and thrombolysis.
Results: 510 patients were included, 392 (77%) white and 118 (23%) non-white. Non-white patients were younger
(median 69 vs. 60 years, p < 0.001), had a higher blood pressure at admission (median systolic 150 vs. 160 mmHg,
p = 0.02) and a lower stroke severity (median NIHSS 5 vs. 4, p = 0.04). Non-white patients were significantly less
often treated with thrombolysis compared to white patients (odds ratio 0.34, 95% CI 0.17-0.71), which was partly
explained by a later arrival at the hospital. After adjustment for potential confounders (late arrival, age, blood
pressure above upper limit for thrombolysis, and oral anticoagulation use), a trend towards a lower thrombolysis
rate in non-whites remained (adjusted odds ratio 0.38, 95% CI 0.13 to 1.16).
Conclusions: Non-white stroke patients less often received thrombolysis than white patients, partly as a result of a
delay in presentation. In this single centre study, potential bias due to hospital differences or insurance status
could be ruled out as a cause. The magnitude of the difference is worrisome and requires further investigation.
Modifiable causes, such as patient delay, awareness of stroke symptoms, language barriers and treatment of
cardiovascular risk factors, should be addressed specifically in these ethnic groups in future stroke campaigns.
Background
Despite its proven efficacy, only a minority of patients
with an acute ischemic stroke are treated with intrave-
nous thrombolysis [1-3]. A delay in hospital presenta-
tion is the most important reason why this treatment is
withheld from stroke patients [4,5]. Other factors asso-
ciated with not receiving thrombolysis are female gen-
der, older age, improving or too mild neurological
deficit and admittance to hospitals that are non-aca-
demic, small, or located in areas with a low population
density [6-9].
Various studies have shown consistently that the level
of medical care is lower in ethnic minorities. Examples
are reperfusion therapy for myocardial infarction [10],
treatment of hypertension [11], and carotid endarterect-
omy [12]. Two studies have investigated the relation
between ethnicity and thrombolysis for acute ischemic
stroke in North-America [13,14]. Both found that black
patients were significantly less likely to undergo throm-
bolysis than white patients. The magnitude of the differ-
ence varied considerably between the studies.
Furthermore, because both were multi-centre studies,
hospital related factors, in addition to ethnicity, may
have attributed to the difference in thrombolysis rate.
The aim of the present study was to investigate the
relation between ethnicity and thrombolysis in a single
academic hospital with a multi-ethnic caption area.
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Study population
We performed a hospital-based study in a large aca-
demic hospital in Amsterdam, the Netherlands. Patients
admitted with an acute ischemic stroke between January
2003 and February 2008 were collected in the Academic
Medical Centre (AMC) stroke registry. For the purpose
of this study, additional data on ethnicity and stroke
treatment were retrospectively collected from the hospi-
tal records and patients interviews. Amsterdam has a
multi-ethnic population; 35% of all inhabitants have a
non-Western ethnicity http://www.os.amsterdam.nl. In
the South-Eastern part of the city, where the hospital is
located, Black and Asian are the most common
ethnicities.
The diagnosis of ischemic stroke was established by a
neurologist or resident in neurology. Stroke severity was
assessed using the National Institutes of Health Stroke
Scale (NIHSS) [15]. Strokes were classified into subtypes
according to the ‘Trial of Org 10172 in Acute Stroke
Treatment’ (TOAST) criteria [16]. Symptom-to-door
times and door-to-needle times (if applicable) were cal-
culated from the medical records. Patients who arrived
within 2.5 hours from symptom onset were deemed
potentially eligible for thrombolysis. We reviewed medi-
cal records to obtain demographic data and baseline
characteristics, and contacted patients by telephone to
determine ethnicity and to complete missing data.
Patients were called at maximally three different occa-
sions. If these attempts failed, or when a patient had
died, a questionnaire was sent to the general practi-
tioner. Ethnicity was determined by self-identification
and stratified into the following six groups: (1) white,
(2) black, (3) Asian, (4) Turkish, (5) Moroccan and (6)
other. For all further analyses, we classified the groups
as white (1) and non-white (all other ethnicities). The
study protocol was approved by the ethical review board
of the Academic Medical Centre.
Thrombolysis protocol
The thrombolysis protocol of the Academic Medical
Centre is based on the study protocol of the National
Institute of Neurological Disorders and Stroke (NINDS)
trial and uses the same selection criteria [17]. Prior to
thrombolysis, all patients undergo a CT-scan to rule out
intracerebral haemorrhage. If thrombolysis within 3
hours of symptom onset is possible (changed to 4.5
hours in September 2008) and no contraindications are
present, the patient receives intravenous alteplase in a
dose of 0.9 mg per kilogram of body weight (maximum,
90 mg), 10 percent of which is given as a bolus followed
by delivery of the remaining 90 percent as a constant
infusion over a period of 60 minutes. The AMC throm-
bolysis protocol does not employ an age-limit, nor is
thrombolysis withheld in patients with a severe stroke.
When the blood pressure is above the upper limit (185
systolic or 110 diastolic), we generally monitor the
blood pressure every 10 minutes. If it spontaneously
drops below the limit, thrombolysis is performed. We
never apply pharmacological reduction of the blood
pressure prior to thrombolysis.
Statistical analysis
Categorical data were analysed with a X
2 test and con-
tinuous data with a Mann-Whitney test. To identify
potential confounders of the relation between ethnicity
and thrombolysis, we used logistic regression analysis.
First, univariate analysis was performed to determine
the association between preselected variables and
thrombolysis (model I). The following variables were
selected: arrival at the hospital within 2.5 hours of
symptom onset, age, gender, previous stroke and dia-
betes, blood pressure above 185 systolic or 110 diastolic,
mild stroke (defined as an NIHSS < 5), severe stroke
(defined as an NIHSS > 25) and oral anticoagulation
use. Next, these variables were entered in a bivariate
model together with ethnicity (model II). If the bivari-
able odds ratio (OR) differed by more than 5% from the
univariate OR for the relation between thrombolysis and
ethnicity, the variable was considered a confounder and
included in multivariate analysis (model III).
Results
From the AMC stroke database, 510 patients with an
a c u t ei s c h e m i cs t r o k ew e r ei n c l u d e d ;3 9 2( 7 7 % )w h i t e
and 118 (23%) non-white. 364 out of the 510 patients
(71%) were contacted by telephone to assess self-
reported ethnicity and, sporadically, other missing
values. Among non-white patients, black (53%) and
Asian (37%) were the most common ethnic groups.
Non-white patients were significantly younger than
whites (69 vs. 60 years, table 1), had a higher body-mass
index (25 vs. 27), a lower stroke severity (NIHSS 5 vs. 4)
and a higher blood pressure at admission, both systolic
(150 vs. 160 mmHg) and diastolic (82 vs. 90 mmHg).
Small-vessel disease was the predominant stroke subtype
in non-white patients, while large-vessel atherosclerosis
and cardioembolic stroke were more common in white
patients. Non-whites more frequently had diabetes (18
vs. 39%), whereas whites were more often previous or
current smokers (64 vs. 47%). White patients more fre-
quently used aspirin (19 vs. 10%) and oral anticoagula-
tion (14 vs. 6%) at baseline.
In total, 85 out of 510 patients (17%) were treated
with thrombolysis. Non-white patients with an acute
ischemic stroke significantly less often received throm-
bolysis compared to white patients (7 vs. 18%, OR 0.34,
95% CI 0.15-0.71, table 2). There was no significant
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times. Thrombolysis rates were similar among Asian
and black ethnicities (both 7%). To identify explanatory
variables for the difference in thrombolysis rate between
white and non-white patients, we analysed the frequency
of potential contraindications for thrombolysis in both
ethnic groups (table 3). Non-white patients arrived at
the hospital outside the time window for thrombolysis
more often than whites (59 vs. 79%, p < 0.001). Non-
white patients also more often had a blood pressure
above 185/110 (17 vs. 28%). On the other hand, whites
more frequently used oral anticoagulation at admission
(14 vs. 6%) and more often were older than 80 (21 vs. 6%).
There was no significant difference in the proportion of
patients with a mild or severe stroke. In the subgroup of
patients without an unconditional contraindication for
thrombolysis (arrival at hospital after 2.5 hours from
symptom onset, blood pressure above 185/110 or oral
anticoagulation use), non-whites were still less often trea-
ted with thrombolysis, although the difference was no
longer significant (45 vs. 29%, p = 0.12).
We performed logistic regression analysis to deter-
mine whether ethnicity was independently associated
with the chance of receiving thrombolysis. First, the
association between thrombolysis and each of the prese-
lected variables was determined separately (table 4,
model I). Then, each variable was entered in a model
together with ethnicity, in order to determine the effect
on the OR (model II). The variable ‘arrival within 2.5
hours’ had the largest effect on the association between
ethnicity and thrombolysis (OR change from 0.34 to
0.60). Other variables that changed the OR by 5% or
more in the bivariate analyses were: age, blood pressure
above 185/110 and oral anticoagulation use. These four
Table 1 Baseline characteristics
White
(n = 392)
Non-white
(n = 118)
P-value
Ethnicity
Black - 53%
Asian - 37%
Turkish - 3%
Moroccan - 1%
Other - 6%
Patient characteristics
Gender (% female) 45% 54% 0.08
Age 69 (59-79) 60 (49-72) < 0.001
BMI 25 (23-27) 27 (24-31) 0.03
Systolic blood pressure 150 (135-176) 160 (140-186) 0.02
Diastolic blood pressure 82 (75-95) 90 (80-100) 0.003
NIHSS 5 (2-12) 4 (2-6) 0.04
TOAST classification
Small-vessel disease 36% 59% < 0.001
Large-vessel disease 40% 25%
Cardioembolic stroke 15% 8%
Other known cause 4% 4%
Undetermined cause 6% 5%
Baseline medication use
Platelet inhibitors
Aspirin 19% 10% 0.02
Dipyridamole 5% 5% 0.99
Clopidogrel 2% 1% 0.32
Oral anticoagulation 14% 6% 0.02
Antihypertensive 49% 43% 0.27
Antihyperlipidemic 26% 18% 0.08
Antidiabetic 15% 29% < 0.001
Cardiovascular risk factors
Hypertension 55% 62% 0.21
Untreated hypertension 23% 32% 0.15
Diabetes 18% 39% < 0.001
Hypercholesterolemia 29% 34% 0.37
Smoking (previous or current) 64% 47% 0.003
Atrial fibrillation 14% 9% 0.11
Previous stroke 23% 20% 0.55
Continuous variables are given as medians with interquartile ranges between
brackets. Abbreviations: BMI = body mass index; NIHSS = National institute of
health stroke scale.
Table 2 Thrombolysis rate in white and non-white
patients
White
(n = 392)
Non-white
(n = 118)
p
value
Intravenous thrombolysis 18% 7% 0.003
Time interval (thrombolysed
patients)
Onset-to-treatment time
(minutes)
105 (80-147) 120 (91-165) 0.51
Door-to-needle time
(minutes)
31 (21-55) 37 (27-114) 0.35
Continuous variables are given as medians with interquartile ranges between
brackets. The data from the onset-to-treatment and door-to-needle times are
derived from patients who received thrombolysis only.
Table 3 Potential contraindications for receiving
thrombolysis
White
(n = 392)
Non-white
(n = 118)
p value
Arrival hospital after 2.5 hours of
symptom onset
59% 79% < 0.001
Blood pressure higher
than 185/110
17% 28% 0.02
NIHSS < 5 48% 56% 0.14
NIHSS > 25 1% 0% 0.44
Age > 80 years 21% 6% < 0.001
Previous stroke and diabetes 6% 7% 0.88
Oral anticoagulation use 14% 6% 0.02
Variables which may potentially explain why patients were not treated with
intravenous thrombolysis. NIHSS = National institute of health stroke scale
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used in the multivariate analysis (model III). After
adjustment for these confounders, there was still a trend
towards a lower thrombolysis rate among non-white
patients, but the association was no longer significant
(adjusted OR 0.38, 95% CI 0.13-1.16, p = 0.09).
Discussion
Non-white patients were two-and-a-half times less
likely to receive thrombolytic treatment than white
patients. An important explanatory variable for this
difference was a later arrival at the hospital of non-
white patients.
Two studies previously investigated the relation
between ethnicity and thrombolysis for acute ischemic
stroke; both found that black patients were significantly
less likely than white patients to receive thrombolysis
[13,14]. For both studies, data were obtained from many
different hospitals throughout the USA. This may pro-
vide a bias with regard to the observed treatment differ-
ence, due to the inter-hospital differences that exist in
the use of thrombolytic treatment [7]. If those hospitals
with lower thrombolysis rates provide care to areas pre-
dominantly inhabited by people from ethnic minorities,
the reported treatment difference could in reality be the
result of differences in hospital related factors, rather
than ethnic factors. Adjustment for hospital factors,
such as bed size and number of stroke admittances, as
both studies did, might only partially correct this bias.
Furthermore, in the study by Schwamm et al, adjust-
ment for stroke severity and uncontrollable hyperten-
sion, two factors that influence the decision to use
thrombolysis, was not possible. Finally, the study by
Johnston et al was performed in 1999, only a few years
after the introduction of thrombolysis for acute ischemic
s t r o k e .A tt h a tt i m es o m eh o s pitals may still have been
in the start-up phase, leading to treatment variations
among hospitals. In contrast, the present study was car-
ried out more than 10 years after the introduction of
thrombolytic therapy in a single academic centre in
Amsterdam. Historically, this hospital serves many dif-
ferent ethnic groups who live in the same relatively
small area. There is no reason to assume that in this
particular region access to medical services or to (pub-
lic) transportation systems would vary for white and
non-white patients. Patients are treated similarly upon
arrival at the hospital. According to Dutch law, hospitals
and doctors are obliged to provide emergency medical
care, including thrombolysis, to any patient regardless of
insurance status. We therefore assume that it is unlikely
that the differences in treatment we identified are
caused by physician biases regarding ethnicity. On the
other hand, insurance status may have had an effect on
whether a patient decided to come to the hospital, and
how fast.
Our study has several limitations. First, some of the
data were collected retrospectively, which increases the
risk of an unknown bias. Second, the relatively small
study size precluded any subgroup analyses regarding
specific ethnic minorities. Finally, to eliminate hospital
related factors, we performed a single-centre study.
Consequently, the results may not be representative of
other hospitals.
An important explanatory variable for the difference
in thrombolysis rate we observed was that non-white
patients more frequently arrived at the hospital outside
the time window for thrombolysis. Several previous stu-
dies have investigated hospital arrival times of ethnic
minorities with an ischemic stroke. Similar to our study,
two of these also found that non-whites arrived at the
hospital significantly later than white patients [18,19].
Smith et al, however, did not find such a difference [20].
Ethnic minorities generally have a lower level of aware-
ness regarding stroke symptoms, as has been found in
several studies [21,22]. Several campaigns, with extensive
TV coverage, have tried to raise stroke awareness in the
Table 4 Logistic regression analysis
OR (95% CI) P-value
I. Univariate model
Ethnicity 0.34 (0.17-0.71) 0.004
Arrival hospital after 2.5 hours of
symptom onset
0.033 (0.005-0.21) < 0.001
Age 0.99 (0.98-1.0) 0.29
Gender 1.8 (1.1-2.9) 0.02
Previous stroke and diabetes 0.48 (0.14-1.6) 0.24
Blood pressure higher than 185/110 0.68 (0.35-1.3) 0.25
NIHSS < 5 8.1 (4.2-16) < 0.001
NIHSS > 25 4.9 (0.30-79) 0.26
Oral anticoagulation use 0.15 (0.035-0.61) 0.008
II. Bivariate model (ethnicity is added to each model)
Arrival hospital after 2.5 hours of
symptom onset
0.60 (0.24-1.50)* 0.28
Age 0.30 (0.14-0.63)* 0.001
Gender 0.36 (0.17-0.74) 0.006
Previous stroke and diabetes 0.34 (0.17-0.71) 0.004
Blood pressure higher than 185/110 0.33 (0.15-0.71)* 0.004
NIHSS < 5 0.36 (0.16-0.78) 0.01
NIHSS > 25 0.34 (0.16-0.73) 0.006
Oral anticoagulation use 0.31 (0.15-0.64)* 0.002
III. Multivariate model 0.38 (0.13-1.16) 0.09
The univariate model (I) shows the odds ratio for receiving thrombolysis for
the variables separately. Next, the association with ethnicity is analysed in the
bivariate model (II), using the same preselected variables. Finally, in the
multivariate model (III) the variables which significantly changed the odds
ratio (age; blood pressure higher than 185/110; oral anticoagulation use;
arrival at the hospital after 2.5 hours of symptom onset) were entered in a
model together with ethnicity.
OR = odds ratio; CI = confidence intervals; NIHSS = National institute of health
stroke scale; * indicates a 5% or greater change in odds ratio.
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112 (emergency medical services) at the first symptom
of stroke. Unfortunately, these campaigns may not have
sufficiently reached people from ethnic minorities, possi-
bly due to cultural differences or language barriers.
After adjustment for the potential confounders, there
was still a trend towards a lower rate of thrombolysis
among non-white patients. Therefore, other, unidentified
factors may have been of influence. One potential factor
could be language barriers among non-white, often
immigrant groups. Such barriers hinder communication
between physicians and patients or their relatives, which
could lead to the inability to ascertain the moment of
symptom onset, or cause delays in taking the patient’s
medical history. Several studies have indeed found that
the presence of language barriers is associated with a
lower level of health care [23,24]. Insufficient treatment
of cardiovascular risk factors, particularly hypertension,
may also be a reason why non-whites less often received
thrombolysis. Patients with inadequately treated hyper-
tension are more likely to have a blood pressure higher
than 185/110, a contraindication for thrombolysis. This
hypothesis is corroborated by the fact that in our study
population there was a trend towards more untreated
hypertensive patients among non-whites than whites. It
is also supported by the aforementioned finding that
black patients are less likely than white patients to receive
medical treatments, including some that are important in
the management of cerebrovascular disease [10-12].
Conclusions
Our results indicate that non-white patients with an
acute ischemic stroke significantly less often receive
thrombolytic treatment than white patients, confirming
results from two North American studies. We identified
that a delay in presentation was one of the most impor-
tant explanatory factors. The additional value of our
study is that hospital related factors and patient health
insurance status could be ruled out as a cause in our
setting. The magnitude of the difference is worrisome
and requires further investigation. Modifiable causes,
such as awareness of stroke symptoms, language bar-
riers, patient delay and treatment of cardiovascular risk
factors, should be addressed specifically in these ethnic
groups in future stroke campaigns.
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